Testing a new HIV medication against an established treatment

Plain-English translation of NCT07711223 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new HIV medication called ACC017 to see if it works as well as dolutegravir, a well-known HIV drug that many people take successfully. Both medications will be combined with two other standard HIV drugs (emtricitabine and tenofovir alafenamide) and given to adults with HIV who have never had HIV treatment before.

Researchers want to develop more treatment options for people with HIV. This medication could offer another effective choice for starting HIV treatment, potentially with different benefits or side effects than existing drugs.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with HIV and have never taken HIV medications before
your HIV viral load is at least 500 copies per milliliter at screening
you are willing and able to follow the study protocol and take medication as directed
you agree not to start any HIV treatment between signing consent and being randomized into the study

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant within three months after stopping the study medication
you have severe, poorly controlled medical conditions such as uncontrolled high blood pressure, advanced heart or lung disease, or severe liver disease
you have serious laboratory abnormalities such as severe anemia, very high liver enzymes, or severely reduced kidney function
you have hepatitis B or C infection that is active or requires treatment
you have taken HIV prevention medications (PrEP or PEP) in the past month or long-acting prevention drugs at any time

What participation looks like

After screening and eligibility confirmation, you will be randomly assigned to take either the new medication ACC017 or the established medication dolutegravir, plus two other standard HIV drugs, once daily for 48 weeks in a blinded phase (meaning you won't know which group you're in). After that, you'll continue taking the new medication openly for another 48 weeks. Throughout the year, you'll visit the clinic regularly for blood tests and check-ups to monitor how well the medication is working and to watch for any side effects.

AI-generated summary from trial data · Aug 7, 2026 · Not medical advice

Testing a new HIV medication against an established treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)